Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Precision BioSciences Highlights Interim Data From Allogeneic CAR T Programs In Blood Cancer Patients

  • Precision BioSciences Inc (NASDAQ:DTILshared new interim data from the Phase 1/2a study of PBCAR0191 for the patient population with aggressive lymphomas.
  • The data demonstrated that PBCAR0191 produced high clinical response rates in CAR T relapsed patients who received a median of five prior lines of therapy. 
  • Evaluable subjects in the study had 100% ORR, 73% CR rate, and 50% durable response rate greater than six months.
  • No Grade 3 or greater cytokine release syndrome (CRS) was observed on the safety front in either dosing cohort. 
  • One Grade 3 immune effector cell-associated neurotoxicity syndrome was recorded in each cohort that rapidly resolved to Grade 1 within 24 to 48 hours. 
  • In the New Cohort, two Grade 5 events associated with late-occurring encephalopathy were suspected to be related to fludarabine-associated neurotoxicity. There was no evidence of graft versus host disease in either cohort.
  • Precision BioSciences held a cash balance of approximately $121 million as of May 31, sufficient to fund its operating expenses and capital expenditure requirements into mid-2023.
  • Price Action: DTIL shares are up 1.91% at $2.13 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.